Continuing Education (CE)
Continuing Education (CE)
Bayer has sponsored a variety of continuing education (CE) programs, which were developed to improve awareness and understanding of oncologic conditions.
All accredited CE/CME programs listed below were created independently by third-party providers and follow the standards set forth in the ACCME Standards for Commercial Support/Integrity and Independence in Accredited Continuing Education, or other similar accrediting organizations. Responsibility and control over selection, content, faculty, educational materials, and venue for the educational programs belong solely to the providers and/or accreditors. Bayer does not provide any guidance regarding the content or faculty for any programs receiving funding.
The list below is limited to CE programs supported by Bayer.
Last updated "April 2025".
Show Me Your Care Plan!™: Nurses on the Forefront of Patient Care, Communication, and Education in Prostate Cancer
Physicians' Education Resource, LLC
1.5 Contact Hours
Intended Audience: Oncologists, Nurses, Physician Assistants
Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care
PVI, PeerView Institute for Medical Education Inc.
1.5 (CME/MOC/NCPD/AAPA/IPCE)
Intended Audience: Radiation Oncologists, Oncologists, Nurses, Urologists
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Prostate Cancer
Research To Practice
2.0 (AMA)
Intended Audience: Physicians
Treatment Strategies Across the Spectrum of Prostate Cancer: Impact of New Agents and Combination Therapies for Urologists
Medical Education Resources
1.0 (AMA)
Intended Audience: Urologists, Oncologists, Nurses, Pharmacists, NPs/PAs and other HCPs who treat patients with prostate cancer
Prostate Cancer Highlights: Expert Review of European Oncology Meeting
Medscape, LLC
0.5 (AMA)
Intended Audience: Oncologists, Urologists, Radiologists, and Other HCPs Who Care for Patients with Prostate Cancer in the US
Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum
PVI, PeerView Institute for Medical Education, Inc.
1.5 (AMA)
Intended Audience: Oncologists, Urologists, Advanced Practice Clinicians, and Other Hcps Involved in the Management of Prostate Cancer
Optimizing Treatment Strategies From mHSPC to mCRPC: Integrating the Latest Data Throughout the Patient Journey
Answers in CME, Inc
1.0 (AMA)
Intended Audience: Global Oncologists (Focusing On Medical And Radiation), Urologists, Nuclear Medicine Specialists, And Other Clinicians
Evolving Treatment Landscape for mHSPC: Latest Clinical Data and Implications for Practice
Medscape, LLC
0.5 (AMA)
Intended Audience: Urologists, Radiation Oncologists, Oncologists, Nurses, Pharmacists and others
Exploring Novel Combinations in mCRPC Care: Radioligands and Beyond
Medscape, LLC
1.25 (AMA)
Intended Audience: Oncologists, Radiologists, Urologists, Surgeons, and any Other Healthcare Specialists Involved in the Care of Patients with Prostate Cancer
Navigating Therapeutic Choices in Prostate Cancer: Effective Decision-Making for Patient-Centric Care
PVI, PeerView Institute for Medical Education, Inc.
1.0 (AMA)
Intended Audience: Urologic, Radiation, and Medical Oncologists; Urologists; Advanced Practice Clinicians; and Other HCPs Involved in the Care of Patients with Prostate Cancer
Comprehensive and Personalized Approach to Managing mHSPC: Fitting the Right Pieces for Each Patient
Medscape, LLC
0.5 (AMA)
Intended Audience: Urologists, Radiation Oncologists, Oncologists, Nurses, Pharmacists and others
Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals
PVI, PeerView Institute for Medical Education, Inc.
1.0 (AMA)
Intended Audience: Urologists, Medical Oncologists, and other Clinicians Involved in the Management of Patients with mCRPC
Updates to Cancer Survivorship: Optimizing Care and Outcomes
Harvard Medical School
20.5 (AMA)
Intended Audience: Primary Care Physicians, Physician Assistants, Nurses, Nurse Practitioners, Specialty Physicians, Psychologists, and Social Workers
Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer
Global Education Group
0.5 (AMA)
Intended Audience: Oncologists, Gastroenterologists, and other clinicians involved in the treatment of mCRC
Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC
Global Education Group
0.5 (AMA)
Intended Audience: Oncologists, Gastroenterologists, and other clinicians involved in the treatment of mCRC
Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care
Global Education Group
0.5 (AMA)
Intended Audience: Oncologists, Gastroenterologists, and other clinicians involved in the treatment of mCRC
Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?
Physicians' Education Resource, LLC
2.0 (AMA)
Intended Audience: Physicians, Pathologists, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists
Exploring HER2 in NSCLC: Defining Gaps and Current Practices
Medscape, LLC
0.25 (AMA)
Intended Audience: Physicians, Pulmonologists, Pathologists, Nurses, and Nurse Practitioners
Biomarker-Driven Management of NSCLC
Springer Healthcare IME
0.75 (AMA)
Intended Audience: Oncologists, Pathologists and those treating patients with NSCLC
Educating, Empowering, and Engaging: A Focus on HER2-Activating Mutations in NSCLC
Medscape, LLC
1.00 (AMA)
Intended Audience: Oncologists, Pulmonologists, Pathologists, Surgeons, Nurses, Pharmacists, and other members of the global and US care team
Fusion Forward: Advances in NTRK Gene Fusion Diagnosis and Treatment for Thyroid Cancer
Global Education Group
0.5 (AMA)
Intended Audience: Oncologists, Pathologists, Endocrinologists, including community clinicians, and other clinicians involved in the treatment of thyroid cancer.
Integrating Advanced Molecular Diagnostic Techniques and Biomarker-Driven Testing Strategies in Precision Oncology: Bridging the Gap for Improved Veteran Patient Outcomes
Med Learning Group
1.0 (AMA)
Intended Audience: VA oncologists, VA pathologists, and nurse practitioners involved in the diagnosis and treatment of cancer patients
Pediatric TRK Fusion-Positive Cancer: Optimizing Care With TRK Inhibitors
Medscape, LLC
0.5 (AMA)
Intended Audience: pediatricians, oncologists (including pediatric oncologists), pathologists, nurse practitioners, physician assistants, nurses, pharmacists, and other members of the care team
PRecision Oncology: Medical Innovations and Scientific Exchange (PROMISE)
Medscape, LLC
Varies
Intended Audience: Physicians, Pathologists, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists
Follow Us
